Medtronic Raised Its Dividend for a 47th Straight Year, But Here's Why It Isn't a Great Dividend Growth Stock
Medtronic has been increasing its dividend for decades. But the rate of its increases has slowed drastically in recent years.
With Less Than 10% Contribution To Sales How Important Is The Diabetes Segment For Medtronic Stock?
Medtronic's (NYSE: MDT) diabetes segment, which sells insulin pumps, continuous glucose monitoring systems, and consumables has seen its revenue rise at a slower pace of 1.4% annually from $2.4 billion in fiscal 2020 (fiscal ends in April) to $2.5 billion in fiscal 2024. The slower growth can be attributed to unfavorable currency translation, given that over 60% of the segment sales are derived from markets outside the U.S. However, we think the company will see a pickup in diabetes sales going forward.
Dividend Delights: 3 Stocks That Will Sweeten Your Investment Returns
Dividend stocks are the best way to play a market potentially on the cusp of a massive rebound, thanks to the Federal Reserve potentially cutting rates three times if inflation stays low, which has made the market more optimistic. The latest Bureau of Economic Analysis report shows that inflation cooled slightly in April.
I'm Buying Dividend Aristocrats With Up To 8.5% Yield
Medtronic and Altria are two value stocks with long track records of raising dividends for over 25 consecutive years. Medtronic is a healthcare technology company with strong revenue growth and a safe dividend yield of 3.4%. Altria, despite challenges in the tobacco industry, offers an 8.5% dividend yield and potential upside from its e-vapor business and strategic investments.
Is Medtronic Stock a Buy?
Medtronic's growth rate has been showing signs of improvement. The company recently announced it would be raising its dividend for the 47th consecutive year.
Medtronic Stock Is a Sell, According to 1 Wall Street Analyst
Medtronic exceeded quarterly forecasts last week, but its stock got punished anyway. Shares cost nearly 30x earnings, but those earnings are growing painfully slowly.
Medtronic: Net Income Could Fall $3.38B, The Stock Would Still Be Undervalued
Medtronic's fair price estimate is $142.20, indicating a 73.3% upside from $82.07, with potential annual returns of 28.8% through 2029. FQ4 2024 earnings exceeded expectations with an EPS of $1.46 and revenue of $8.59 billion. Medtronic focuses on innovation through AI, data analytics, and new partnerships, enhancing competitiveness and product offerings.
Medtronic Stock Could Soar 29%, According to a Wall Street Analyst. Is the Dividend Champion a Buy Now?
Medtronic stock reacted negatively to an earnings report that many Wall Street analysts found encouraging. Wells Fargo raised its price target for Medtronic to $105 per share.
Medtronic's (MDT) OmniaSecure Lead Favored in the LEADR Trial
Medtronic's (MDT) OmniaSecure defibrillation lead demonstrates reliable performance in the LEADR Pivotal trial.
Medtronic Dips: Is Now the Time to Buy?
Shares of Medtronic NYSE: MDT are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow are enough to keep investors interested and if they should be.
Medtronic's Mixed Q4 Earnings Report
Medtronic's top line saw growth in Q4 and full-year, but that growth disappeared in the bottom-line figures. Medtronic management was positive in its outlook for fiscal 25 with projected organic revenue growth of 4%-5%.
Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down
Growth across Cranial & Spinal Technologies, Diabetes, Cardiac Pacing and Surgical businesses contributes to Medtronic's (MDT) Q4 revenues.
